(MedPage Today) — Camrelizumab, an investigational immunotherapy, on top of adjuvant capecitabine (Xeloda) and radiotherapy, improved survival outcomes in patients with resectable biliary tract cancers (extrahepatic cholangiocarcinoma [EHC] and…
Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/116452
Author :
Publish date : 2025-07-10 17:25:00
Copyright for syndicated content belongs to the linked Source.
